In a 65-year-old patient with a prior wrist fracture who has been treated with alendronate (Fosamax) and zoledronic acid (Reclast), experienced a metatarsal fracture while on therapy, and now shows a T‑score of –2.3 with a 6 % decline in lumbar spine bone mineral density despite stable hip BMD, what is the next step in management?

Switch to Anabolic Therapy with Teriparatide or Romosozumab

This patient has experienced treatment failure on sequential bisphosphonate therapy (fracture while on treatment, continued BMD decline despite Reclast), and should be transitioned to anabolic therapy—specifically teriparatide or romosozumab—followed by sequential antiresorptive treatment.

Clinical Reasoning

This 65-year-old patient demonstrates clear antiresorptive treatment failure:

• Sustained a metatarsal fracture while actively on alendronate 1
• Despite switching to zoledronic acid (Reclast) and receiving 2 doses, shows 6% BMD decline at spine with T-score of -2.3
• Has now fractured on two different bisphosphonates, suggesting inadequate response to antiresorptive monotherapy

The metatarsal fracture while on bisphosphonates raises concern for an atypical fracture pattern 1, though the subsequent BMD decline suggests the primary issue is treatment inadequacy rather than over-suppression of bone turnover.

Recommended Treatment Algorithm

First-Line: Anabolic Agent

Option 1: Romosozumab (Preferred)

• Provides the most dramatic BMD increases (73% vertebral fracture reduction vs placebo at 12 months) 2
• Dual mechanism: increases bone formation while decreasing resorption
• Given for 12 months, then transition to antiresorptive therapy
• Particularly effective in high-risk patients with treatment failure 2

Option 2: Teriparatide

• Increases BMD through bone formation 2
• Given daily for up to 24 months maximum 2
• Critical caveat: Must be followed by antiresorptive therapy to prevent rapid BMD loss 2, 3
• Avoid "washout period"—start antiresorptive immediately after completing teriparatide 2

Sequential Antiresorptive Therapy

After completing anabolic therapy (12 months romosozumab or up to 24 months teriparatide):

Transition to denosumab rather than returning to bisphosphonates:

• This patient has already failed two different bisphosphonates
• Denosumab provides potent antiresorptive effect without skeletal retention
• Prevents the BMD loss that occurs after stopping anabolic agents 2
• Critical warning: Denosumab requires indefinite continuation or careful transition strategy to prevent rebound vertebral fractures 4

Key Management Points

What NOT to Do

• Do not continue Reclast: Patient has demonstrated treatment failure with 6% BMD decline 5
• Do not implement a drug holiday: This patient is actively losing bone and has sustained fractures—she needs treatment intensification, not cessation
• Do not switch to oral alendronate: Already failed this medication with fracture while on treatment

Monitoring During Anabolic Therapy

• Measure serum calcium at least 16 hours after teriparatide administration if checking levels 2
• Mild, transient hypercalcemia can occur but is uncommon 2
• Monitor for orthostatic hypotension with first few doses 2

Critical Pitfall: Denosumab Discontinuation

If denosumab is chosen as the sequential antiresorptive agent after anabolic therapy, never stop denosumab abruptly 4:

• Causes rapid rebound bone loss and multiple vertebral fractures
• Requires transition to bisphosphonates if discontinuation is necessary
• Patients with prior vertebral fractures are at highest risk for rebound fractures 4

Contraindications to Screen For

Before starting teriparatide, ensure patient does NOT have 2:

• Paget disease of bone
• Prior skeletal irradiation
• Unexplained elevated alkaline phosphatase
• Primary hyperparathyroidism (untreated)

Supporting Evidence

The 2020 AACE/ACE guidelines explicitly state that after anabolic therapy, "there is no apparent rationale for a 'washout period' or 'drug holiday' between the end of anabolic therapy and the initiation of antiresorptive treatment" 2. The DATA-switch study demonstrated that transitioning from denosumab to teriparatide causes BMD decreases 4, but the reverse sequence (anabolic followed by antiresorptive) maintains and builds upon gains.

Research confirms that switching from failed bisphosphonate therapy to teriparatide or denosumab produces further BMD increases 3, making this the appropriate strategy for treatment failure cases.

The atypical fracture concern (metatarsal fracture on bisphosphonates) 1, 6 actually supports transitioning away from antiresorptive monotherapy toward anabolic agents, which can help with fracture healing if this was indeed an atypical stress fracture pattern 4.